Guardant Health, Inc. raised financial guidance for the full year of 2024. For the period, the company expects revenue excluding screening to be in the range of $675 to $685 million, representing growth of 20% to 21% compared to full year 2023 This compares to the prior range of $655 to $670 million, representing growth of 16% to 19%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.41 USD | +1.14% | +7.41% | +1.33% |
06-03 | Jefferies Initiates Guardant Health at Buy Rating With $32 Price Target | MT |
05-24 | Sector Update: Health Care Stocks Softer in Friday Afternoon Trading | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.33% | 3.32B | |
-39.42% | 8.39B | |
+2.95% | 2.48B | |
-19.81% | 2.06B | |
-23.12% | 1.59B | |
+33.59% | 1.15B | |
-7.21% | 704M | |
+11.33% | 678M | |
-32.45% | 508M | |
-6.86% | 273M |
- Stock Market
- Equities
- GH Stock
- News Guardant Health, Inc.
- Guardant Health, Inc. Raises Financial Guidance for the Full Year of 2024